As final US drug fails, SciClone focuses on breaking China
This article was originally published in Scrip
Executive Summary
Getting out of drug development is not generally a seen a value-creating move, but SciClone Pharmaceuticals turned lemons into lemonade on 2 March when it announced that it would no longer pursue approval by the US FDA of its Phase II oral mucositis drug SCV-07, enabling the company to focus solely on its China business strategy.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.